🇦🇺 Australia · Harrison.ai — Australian Medical AI Company
Status: 🟩 COMPLETE 🟦 LIVING Section: 10 — AI and LLMs
| Vendor | Harrison.ai |
| Country/origin | 🇦🇺 Australia (Sydney; founded 2018) |
| Recommended for AUS? | ✅ Strongly yes — Australian-built medical AI; TGA engagement; clinical-grade |
| Privacy summary | Australian-led data governance; clinical-grade data handling; TGA-engaged products; HIPAA capable for international deployments |
| Free tier | ❌ Enterprise medical only |
| Paid tiers | Hospital/diagnostic provider contracts |
| First released | Founded 2018; Annalise.ai launched 2019; major international expansion 2022-2026 |
| Last reviewed | June 2026 |
| Official site | https://harrison.ai |
What it is
Harrison.ai is the parent company behind some of Australia’s most successful medical AI products — and one of the most internationally significant Australian AI companies overall. Founded in 2018 by brothers Aengus Tran (radiologist) and Dimitry Tran (technologist), Harrison.ai builds diagnostic AI tools deployed across Australia, the UK, and other international markets.
The company is named after John Harrison, the 18th-century English clockmaker who invented the marine chronometer — solving the centuries-old “longitude problem” through precision engineering. The naming reflects Harrison.ai’s mission: solving difficult medical diagnostic problems through precision AI.
Harrison.ai’s product portfolio:
- Annalise.ai — radiology AI (chest X-ray, CT brain) — see annalise-ai
- Franklin.ai — pathology AI (digital pathology for diagnostic interpretation)
- Other diagnostic AI ventures in development
Harrison.ai serves as the platform and infrastructure for these vertical-specific medical AI products.
Why Harrison.ai matters globally
Harrison.ai represents one of the most significant Australian AI exports. As of mid-2026:
- Major international funding — substantial Series B/C raises with international VC participation
- International deployment — products used across UK NHS, European hospitals, and other markets
- Strategic partnerships — major imaging providers (I-MED in Australia, Sonic Healthcare globally)
- Academic credibility — peer-reviewed clinical research published in top medical journals
- Regulatory engagement — TGA, FDA, CE-marked across products
For Australian technology, Harrison.ai represents a globally credible medical AI export.
The Tran brothers’ story
The founding story is genuinely interesting:
Aengus Tran was a radiologist working clinical shifts and observing the limitations of human-only review at scale. He saw the volume of imaging Australia produces (and globally) and the difficulty radiologists face maintaining quality across long shifts.
Dimitry Tran had a technology background. Together they founded Harrison.ai with the thesis that diagnostic AI, properly built and validated, could help radiologists maintain quality at scale.
Their approach differed from many AI startups:
- Clinical rigour first — substantial clinical validation before deployment
- Regulatory engagement — TGA and international approvals from early stage
- Radiologist partnership — building tools radiologists wanted to use, not replacing them
- Australian deployment as proving ground — local market validation before international expansion
This methodical, clinically-rigorous approach has been a competitive advantage in a market where many AI startups struggled with regulatory and clinical adoption hurdles.
Funding and growth
Harrison.ai has raised substantial venture funding:
- Series A (2019/2020)
- Series B (~2021)
- Series C (~2023)
- Continued growth funding (2024-2026)
Investors have included international venture firms and strategic medical/healthcare investors. The company’s valuation reflects expectations of substantial international growth in medical AI markets.
Why Australian medical AI matters
Harrison.ai represents Australia’s serious capability in medical AI. The advantages:
For Australian healthcare:
- Australian clinical context built into products
- TGA regulatory familiarity
- Australian data sovereignty considerations
- Local support and ongoing development
- Australian clinical research partnerships
For Australian technology:
- Demonstrates that Australia can produce globally-significant AI companies
- Builds Australian AI talent and expertise
- Creates economic value from Australian research
- Strengthens Australia’s position in international AI ecosystem
For global healthcare:
- High-quality diagnostic AI built with clinical rigour
- Australian regulatory standards transferring to international approvals
- Clinically-validated outcomes
Harrison.ai’s competitive position
In the global medical AI market, Harrison.ai’s distinctive position:
Strengths:
- Clinical rigour and validation
- Multi-finding detection (broader than narrow-focus competitors)
- Regulatory engagement across multiple jurisdictions
- Clinical partner relationships
- Australian origin (perceived as quality healthcare market)
Challenges:
- Competing with deep-pocketed US and Israeli medical AI companies
- Hospital procurement cycles are slow
- International market expansion is capital-intensive
- Reimbursement models for diagnostic AI vary by country
Harrison.ai vs the broader Australian medical AI scene
Harrison.ai is one of several significant Australian medical AI companies:
| Company | Focus | Status |
|---|---|---|
| Harrison.ai | Diagnostic imaging AI | Largest; international |
| Heidi Health | Clinical documentation | Growing rapidly |
| Lyrebird Health | Clinical documentation | Newer entrant |
| Annalise.ai (Harrison subsidiary) | Radiology specifically | Subsidiary |
| Franklin.ai (Harrison subsidiary) | Pathology | Subsidiary |
| Pulse | Clinical documentation | Newer |
| Coviu | Telehealth platform with AI | Established |
| CSIRO Data61 | Medical AI research | Government research |
Australia has emerged as a meaningful centre for medical AI development — Harrison.ai is the largest commercial player.
How Harrison.ai products are sold
Harrison.ai sells to:
- Hospital systems
- Large diagnostic imaging providers
- Tele-radiology services
- Pathology labs (via Franklin.ai)
- Research institutions
Procurement involves:
- Clinical evaluation
- IT integration assessment
- Regulatory/compliance review
- Financial modelling
- Pilot deployments before full rollout
This is enterprise B2B sales, not consumer products.
Privacy and ethical considerations
Harrison.ai operates in a heavily regulated space:
- TGA Class IIb medical devices for Australian deployments
- FDA clearances for US deployments
- CE marking for European deployments
- Hospital data governance integration
- Clinical validation ongoing
- Adverse event reporting as required for medical devices
For patient privacy:
- Australian Privacy Act protections for Australian patients
- Sensitive information handling for health data
- Integration with hospital privacy frameworks
The future of Harrison.ai
Based on public information and industry direction:
- More vertical products expected — additional diagnostic AI domains
- International expansion ongoing
- Deeper clinical integration — beyond detection to workflow optimisation
- Partnerships with healthcare AI platforms likely
- Potential IPO consideration as company matures
Harrison.ai represents a long-term Australian AI success story still being written.
Gotchas
- Not consumer-accessible. Patients don’t interact with Harrison.ai products directly.
- Enterprise sales cycles are long. Hospital procurement takes months to years.
- Regulatory pathways differ by country. What’s approved in Australia may not be approved in the US, EU, etc.
- AI as decision support, not replacement. Radiologists, pathologists, and other clinicians remain decision-makers.
- Clinical evidence is ongoing. AI performance studies continue; understanding limitations matters.
See also
- annalise-ai — Harrison’s radiology subsidiary
- heidi-health — Australian clinical documentation alternative category
- hippocratic-ai — different medical AI category (US)
- openevidence — clinical knowledge AI
- australian-ai-scene — Australian AI context
- australian-privacy-considerations
Sources
- Harrison.ai official: harrison.ai
- Annalise.ai official: annalise.ai
- Franklin.ai official: franklin.ai
- Australian Financial Review coverage of Harrison.ai (2020-2026)
- Series A/B/C funding announcements
- TGA medical device register
- Sonic Healthcare and I-MED partnership announcements
- Aengus Tran and Dimitry Tran public profiles and interviews